1. Home
  2. IBRX vs TSLX Comparison

IBRX vs TSLX Comparison

Compare IBRX & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBRX
  • TSLX
  • Stock Information
  • Founded
  • IBRX 2014
  • TSLX 2010
  • Country
  • IBRX United States
  • TSLX United States
  • Employees
  • IBRX N/A
  • TSLX N/A
  • Industry
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • TSLX Investment Managers
  • Sector
  • IBRX Health Care
  • TSLX Finance
  • Exchange
  • IBRX Nasdaq
  • TSLX Nasdaq
  • Market Cap
  • IBRX 2.3B
  • TSLX 2.2B
  • IPO Year
  • IBRX N/A
  • TSLX 2014
  • Fundamental
  • Price
  • IBRX $2.26
  • TSLX $22.66
  • Analyst Decision
  • IBRX Strong Buy
  • TSLX Buy
  • Analyst Count
  • IBRX 6
  • TSLX 9
  • Target Price
  • IBRX $9.83
  • TSLX $23.67
  • AVG Volume (30 Days)
  • IBRX 9.4M
  • TSLX 593.0K
  • Earning Date
  • IBRX 11-10-2025
  • TSLX 11-04-2025
  • Dividend Yield
  • IBRX N/A
  • TSLX 9.01%
  • EPS Growth
  • IBRX N/A
  • TSLX N/A
  • EPS
  • IBRX N/A
  • TSLX 2.01
  • Revenue
  • IBRX $56,600,000.00
  • TSLX $474,291,000.00
  • Revenue This Year
  • IBRX $629.94
  • TSLX N/A
  • Revenue Next Year
  • IBRX $109.91
  • TSLX N/A
  • P/E Ratio
  • IBRX N/A
  • TSLX $11.28
  • Revenue Growth
  • IBRX 4227.22
  • TSLX 0.15
  • 52 Week Low
  • IBRX $1.83
  • TSLX $18.58
  • 52 Week High
  • IBRX $5.88
  • TSLX $25.17
  • Technical
  • Relative Strength Index (RSI)
  • IBRX 39.09
  • TSLX 53.64
  • Support Level
  • IBRX $2.30
  • TSLX $22.36
  • Resistance Level
  • IBRX $2.67
  • TSLX $23.19
  • Average True Range (ATR)
  • IBRX 0.12
  • TSLX 0.42
  • MACD
  • IBRX -0.02
  • TSLX 0.16
  • Stochastic Oscillator
  • IBRX 1.19
  • TSLX 73.77

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Share on Social Networks: